BR112022017923A2 - Tratamento de infecção por coronavírus - Google Patents
Tratamento de infecção por coronavírusInfo
- Publication number
- BR112022017923A2 BR112022017923A2 BR112022017923A BR112022017923A BR112022017923A2 BR 112022017923 A2 BR112022017923 A2 BR 112022017923A2 BR 112022017923 A BR112022017923 A BR 112022017923A BR 112022017923 A BR112022017923 A BR 112022017923A BR 112022017923 A2 BR112022017923 A2 BR 112022017923A2
- Authority
- BR
- Brazil
- Prior art keywords
- coronaviruses
- treat
- virus infection
- corona virus
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062987429P | 2020-03-10 | 2020-03-10 | |
| US202063003601P | 2020-04-01 | 2020-04-01 | |
| US202063034817P | 2020-06-04 | 2020-06-04 | |
| US202063074799P | 2020-09-04 | 2020-09-04 | |
| US202063125427P | 2020-12-15 | 2020-12-15 | |
| PCT/IB2021/000131 WO2021181157A1 (en) | 2020-03-10 | 2021-03-08 | Treatment of coronavirus infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022017923A2 true BR112022017923A2 (pt) | 2022-10-18 |
Family
ID=76548186
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022017923A BR112022017923A2 (pt) | 2020-03-10 | 2021-03-08 | Tratamento de infecção por coronavírus |
Country Status (11)
| Country | Link |
|---|---|
| US (6) | US11052073B1 (https=) |
| EP (1) | EP4117630A4 (https=) |
| JP (1) | JP7822946B2 (https=) |
| KR (1) | KR20220151613A (https=) |
| CN (2) | CN117695284B (https=) |
| AU (1) | AU2021235304A1 (https=) |
| BR (1) | BR112022017923A2 (https=) |
| CA (1) | CA3174438A1 (https=) |
| IL (1) | IL295658A (https=) |
| MX (1) | MX2022011173A (https=) |
| WO (1) | WO2021181157A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210244705A1 (en) * | 2020-02-07 | 2021-08-12 | Centre For Digestive Diseases | Therapeutic compositions, products of manufacture and methods for ameliorating or preventing coronavirus infection |
| CN117695284B (zh) | 2020-03-10 | 2025-06-17 | 红山生物医药有限公司 | 冠状病毒感染的治疗 |
| US11471448B2 (en) * | 2020-12-15 | 2022-10-18 | Redhill Biopharma Ltd. | Sphingosine kinase 2 inhibitor for treating coronavirus infection in moderately severe patients with pneumonia |
| CN113398219A (zh) * | 2021-06-30 | 2021-09-17 | 广州白云山星群(药业)股份有限公司 | 橘红痰咳浸膏在制备抑制人冠状病毒感染的药物中的用途 |
| EP4286851A1 (en) | 2022-06-01 | 2023-12-06 | Universität Wien | Methods and means for molecular characterization of post-viral fatigue syndrome |
| WO2025133697A2 (en) * | 2023-12-20 | 2025-06-26 | Redhill Biopharma Ltd. | Combination therapy for inhibition of ebolavirus |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7342018B2 (en) | 1998-07-20 | 2008-03-11 | Wilex Ag | Urokinase inhibitors and uses thereof |
| US6624169B1 (en) | 1998-07-20 | 2003-09-23 | Wilex Biotechnology Gmbh | Urokinase inhibitors |
| AU9059798A (en) | 1998-09-18 | 2000-04-10 | Pentapharm Ag | Urokinase inhibitors |
| DE50211672D1 (de) | 2001-03-21 | 2008-03-27 | Wilex Ag | Urokinase-inhibitoren |
| CH695999A5 (de) | 2002-02-28 | 2006-11-15 | Wilex Ag | Verfahren zur Herstellung von 3- Amidinophenylalanin-Derivaten. |
| WO2004011449A2 (de) | 2002-07-25 | 2004-02-05 | Wilex Ag | Verfahren zur herstellung von phenylalanin-derivaten |
| DE10238048A1 (de) | 2002-07-25 | 2004-02-05 | Wilex Ag | Verfahren zur Herstellung von Phenylalanin-Derivaten |
| US9770349B2 (en) * | 2002-11-13 | 2017-09-26 | University Of Virginia Patent Foundation | Nanoporous stents with enhanced cellular adhesion and reduced neointimal formation |
| DE10323898A1 (de) | 2003-05-26 | 2004-12-23 | Wilex Ag | Hydroxyamidin- und Hydroxyguanidin-Verbindungen als Urokinase-Hemmstoffe |
| RU2234313C1 (ru) | 2003-06-04 | 2004-08-20 | Кривошеин Юрий Семенович | Средство инактивации коронавирусов |
| GB0420874D0 (en) | 2004-09-20 | 2004-10-20 | Swetree Technologies Ab | Modulation of flowering time and growth cessation in perennial plants |
| DE102004045720A1 (de) | 2004-09-21 | 2006-03-23 | Wilex Ag | Stabile Dosierungsform von Phenylalanin-Derivaten |
| BRPI0516106B1 (pt) | 2004-10-14 | 2021-08-24 | Wilex Ag | Métodos para purificação e preparação de derivados de 3-hidroxiamidinofenilalanina, e para produção de derivados de 3-amidinofenilalanina |
| DE102004057195A1 (de) | 2004-11-26 | 2006-06-01 | Wilex Ag | Kristalline Modifikationen von N-Alpha-(2,4,6-Triisopropylphenylsulfonyl)-3-hydroxyamidino-(L)-phenylalanin-4-ethoxycarbonylpiperazid und/oder Salzen davon |
| US8324237B2 (en) | 2005-05-20 | 2012-12-04 | Smith Charles D | Methods for the treatment and prevention of inflammatory diseases |
| ES2528451T3 (es) | 2005-06-17 | 2015-02-10 | Apogee Biothechnology Corporation | Inhibidores de esfingosina cinasa |
| WO2012166859A2 (en) * | 2011-06-01 | 2012-12-06 | The Curators Of The University Of Missouri | Modulation of sphingosine 1-phosphate metabolizing enzymes for the treatment of negative-strand rna virus infections |
| WO2015161908A1 (en) * | 2014-03-11 | 2015-10-29 | Ludwig-Maximilians-Universität München | Non-immunosuppressive cyclophilin inhibitors for the treatment of coronavirus infections |
| CA2965258C (en) * | 2014-10-24 | 2023-09-19 | Redhill Biopharma Ltd. | Therapy for inhibition of single-stranded rna virus replication |
| DK3297438T3 (da) * | 2015-05-21 | 2022-01-17 | Chemocentryx Inc | Ccr2-modulatorer |
| WO2017060771A2 (en) * | 2015-10-06 | 2017-04-13 | Redhill Biopharma Ltd. | Combination therapies for treating cancer |
| US10195188B2 (en) * | 2016-06-13 | 2019-02-05 | Chemocentryx, Inc. | Method of treating pancreatic cancer |
| US10251888B2 (en) * | 2016-06-13 | 2019-04-09 | Chemocentryx, Inc. | Method of treating pancreatic cancer |
| DE102018217334A1 (de) * | 2018-10-10 | 2020-04-16 | Harbins Ruhr Bioscience, Inc. | Sphingoid-Base und/oder Wirkstoff zur Verwendung bei der Prophylaxe und/oder Therapie einer viralen Infektion und/oder viralen Infektionskrankheit oder der Desinfektion, Nahrungsmittel/Nahrungsergänzungsmittel, Futtermittel/Futterergänzungsmittel und Pflanzenschutzmittel |
| CN117695284B (zh) * | 2020-03-10 | 2025-06-17 | 红山生物医药有限公司 | 冠状病毒感染的治疗 |
| EP4126234A1 (en) | 2020-04-02 | 2023-02-08 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Compositions for coronavirus infection treatment and/or prevention |
-
2021
- 2021-03-08 CN CN202311591091.6A patent/CN117695284B/zh active Active
- 2021-03-08 JP JP2022554382A patent/JP7822946B2/ja active Active
- 2021-03-08 US US17/195,279 patent/US11052073B1/en active Active
- 2021-03-08 KR KR1020227029182A patent/KR20220151613A/ko active Pending
- 2021-03-08 BR BR112022017923A patent/BR112022017923A2/pt unknown
- 2021-03-08 EP EP21768527.0A patent/EP4117630A4/en active Pending
- 2021-03-08 CA CA3174438A patent/CA3174438A1/en active Pending
- 2021-03-08 CN CN202180022144.5A patent/CN115515560B/zh active Active
- 2021-03-08 AU AU2021235304A patent/AU2021235304A1/en active Pending
- 2021-03-08 WO PCT/IB2021/000131 patent/WO2021181157A1/en not_active Ceased
- 2021-03-08 MX MX2022011173A patent/MX2022011173A/es unknown
- 2021-03-08 US US17/195,333 patent/US11045453B1/en active Active
- 2021-03-08 IL IL295658A patent/IL295658A/en unknown
- 2021-06-10 US US17/344,430 patent/US11918560B2/en active Active
- 2021-06-30 US US17/364,386 patent/US12551469B2/en active Active
- 2021-10-15 US US17/502,932 patent/US11364227B2/en active Active
-
2024
- 2024-01-30 US US18/426,914 patent/US12502381B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US11918560B2 (en) | 2024-03-05 |
| CN117695284A (zh) | 2024-03-15 |
| IL295658A (en) | 2022-10-01 |
| US11052073B1 (en) | 2021-07-06 |
| US12551469B2 (en) | 2026-02-17 |
| CN115515560A (zh) | 2022-12-23 |
| US11045453B1 (en) | 2021-06-29 |
| KR20220151613A (ko) | 2022-11-15 |
| JP2023517920A (ja) | 2023-04-27 |
| CN115515560B (zh) | 2023-12-15 |
| CN117695284B (zh) | 2025-06-17 |
| MX2022011173A (es) | 2022-10-18 |
| CA3174438A1 (en) | 2021-09-16 |
| US20240350461A1 (en) | 2024-10-24 |
| US20210299108A1 (en) | 2021-09-30 |
| US12502381B2 (en) | 2025-12-23 |
| AU2021235304A1 (en) | 2022-10-06 |
| EP4117630A1 (en) | 2023-01-18 |
| US11364227B2 (en) | 2022-06-21 |
| EP4117630A4 (en) | 2024-07-03 |
| JP7822946B2 (ja) | 2026-03-03 |
| WO2021181157A1 (en) | 2021-09-16 |
| US20220031682A1 (en) | 2022-02-03 |
| US20210322390A1 (en) | 2021-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022017923A2 (pt) | Tratamento de infecção por coronavírus | |
| PH12022552794A1 (en) | Antiviral application of nucleoside analog or combination formulation containing nucleoside analog | |
| BR112021022624A2 (pt) | Compostos para o tratamento da doença de huntington | |
| BRPI0210076A8 (pt) | Preparação de vírus da influenza inativado, vacina de influenza, método para a preparação de um antígeno de hemaglutinina estável, e, uso de alfa-tocoferol ou succinato | |
| BR112022000503A2 (pt) | Compostos úteis para tratar infecções por vírus influenza | |
| BR112023025358A2 (pt) | Inibidores de protease como antivirais | |
| BR112022021962A2 (pt) | Imidazopiridazinas como moduladores de il-17 | |
| BR112022020147A2 (pt) | Compostos para tratar a doença de huntington | |
| BR112022017209A2 (pt) | Uso de composto nucleosídeo no tratamento de doenças infecciosas por coronavírus | |
| BR112023002951A2 (pt) | Compostos de fosfolipídio e usos destes | |
| BR112012009376A2 (pt) | composição farmacêutica, forma de dosagem farmacêutica, processo para a sua preparação, métodos de tratamento e seu uso | |
| BRPI0411906A (pt) | compostos, processo para a sua preparação, composições farmacêuticas que compreendem os mesmos, método para tratar ou prevenir uma enfermidade mediada pela ativação da enzima de sintase de glicogênio, e utilização dos compostos | |
| BR112015028879A8 (pt) | compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos | |
| BR0113755A (pt) | Composto multimérico, processo para a preparação de composto, composição farmacêutica que compreende o composto, processo para o tratamento e/ou profilaxia e detecção de uma infecção por virus, utilização do composto, e inalador que contém a composição | |
| BRPI0517934A (pt) | métodos de captura, inativação e remoção de infecções virais mediante a administração de composições para o trato respiratório | |
| BRPI0512335A (pt) | compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades e sua utilização | |
| BRPI0409498A (pt) | uso de um composto, formulação farmacêutica, composto, composição farmacêutica, e, processo para preparação de um composto | |
| WO2022129097A3 (en) | Sirna and compositions for prophylactic and therapeutic treatment of virus diseases | |
| BR112022019198A2 (pt) | Composição farmacêutica para a prevenção ou tratamento de infecções por vírus de ácido ribonucleico epidêmico, e, uso de uma quantidade terapeuticamente eficaz de pironaridina ou um sal farmaceuticamente aceitável da mesma e artemisinina ou um derivado da mesma | |
| BR112022024149A2 (pt) | Anticorpos antiglicoproteína spike de anti-sars-cov-2 e fragmentos de ligação a antígeno | |
| BR112018015629A2 (pt) | ?composto, composição, método para tratar um mamífero infectado com o vírus hiv, e, proteína mutante tripla? | |
| BR112022021640A2 (pt) | Usos e formulações de canabinoides | |
| BRPI0418103A (pt) | extrato aquoso do córtex da canela, uso de um extrato de canela, composição, métodos para o tratamento de um paciente que esteja sofrendo de infecção viral e para desinfetar uma área suspeita de ter sido contaminada com vìrus, filtro, método para produzir um vìrus neutralizado para imunização, vìrus neutralizado, formulação de vacina e, método de imunização contra infecção viral | |
| MX2021010834A (es) | Compuesto y metodo para la prevencion de transmision del virus de influenza. | |
| BR112022014278A2 (pt) | Conjugados de composto proteico-antiviral |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |